Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Case
Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
<p>Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.</p>